Cognitive behaviour therapy for anxiety in psychosis: A systematic review and meta-analysis

David Heavens\textsuperscript{a*}, Kesley Odgers\textsuperscript{a} and Joanne Hodgekins\textsuperscript{b}

\textsuperscript{a}Central Norfolk Early Intervention Team, Norfolk and Suffolk NHS Foundation Trust, Norwich, U.K.

\textsuperscript{b}Department of Clinical Psychology, University of East Anglia, Norwich, U.K.

\textsuperscript{*}Corresponding author: Dr David Heavens, Central Norfolk Early Intervention Team, Norfolk and Suffolk NHS Foundation Trust, 80 St. Stephen’s Road, Norwich, NR1 3RE, U.K. Tel: +44 330 058 1840; e-mail: dave.heavens@nsft.nhs.uk.
Cognitive behaviour therapy for anxiety in psychosis: A systematic review and meta-analysis

Abstract.

Background: Anxiety is common in people with psychosis. Cognitive Behaviour Therapy (CBT) is an effective treatment for anxiety in people without psychosis. Given the prevalence of anxiety in those with psychosis, the efficacy of CBT in this population is important to consider. This review and meta-analysis therefore investigates the efficacy of CBT for anxiety in people with psychosis.

Method: Twenty-nine studies were identified through systematic review, including controlled, uncontrolled and case report designs. Seventeen controlled and uncontrolled studies were included in the quantitative synthesis.

Results: A medium, significant effect was found at post-treatment and follow-up when controlled and uncontrolled data were combined. For controlled between-groups data only, a small, significant effect was found at post-treatment and follow-up. The effect of CBT for anxiety on psychotic symptoms was investigated, resulting in a medium, significant effect for controlled and uncontrolled post-treatment data and a small, significant effect for controlled between-group data.

Conclusions: CBT might have some effect in treating anxiety in people with psychosis. However, this review highlights a lack of scientifically rigorous studies in this area. Further research is required, including the use of well-designed randomised controlled trials (RCTs).
**Keywords:** psychosis; schizophrenia; anxiety; cognitive behaviour therapy; systematic review, meta-analysis

**Introduction**

Anxiety is common in people with psychosis, resulting in distress and poor clinical outcomes (Pallanti et al., 2004). Although anxiety may be understood as a response to the experience of psychosis, it can also predate psychosis and present as co-morbid conditions (Howells et al, 2017). Achim et al. (2011) found that 38.3% of individuals with schizophrenia also met criteria for at least one anxiety disorder. Rates varied, with social anxiety being the most prevalent at 14.9%, followed by post-traumatic stress disorder (PTSD; 12.4%) and obsessive compulsive disorder (OCD; 12.4%).

The role of anxiety is highlighted in cognitive-behavioural models of psychosis. Garety et al. (2001) suggest that anxiety leads to a ‘search for meaning’ in relation to psychotic symptoms, resulting in interpretations associated with threat. In support, Freeman et al. (2002) note that psychological processes involved in anxiety, such as threat, are implicated in the content of persecutory delusions. In further support, Morrison’s (2001) model describes psychotic symptoms as ‘intrusions into awareness’ and argues that these intrusions are maintained by common anxiety processes, such as attentional bias, safety behaviours and thought suppression.

Cognitive Behaviour Therapy (CBT) has been shown to be effective for anxiety in people without psychosis. In a meta-analysis of randomised placebo-controlled trials of CBT for anxiety disorders, Hofmann and Smits (2008) reported a
pooled effect size of 0.73 (95% confidence interval (CI), 0.88-1.65). Effect sizes ranged from 0.35 for panic disorder to 1.37 for OCD. More recently, Carpenter et al. (2018) found a pooled effect size of 0.56, with a small effect on quality of life (Hedges’ g = 0.30). As found by Hofmann and Smits (2008), the largest effects were found in studies of CBT for OCD (Hedges’ g = 1.13, 95% CI = 0.58-1.68, p < .001).

Whilst systematic reviews and meta-analyses investigating CBT for different types anxiety have been conducted (e.g. OCD; Schirmbeck and Zink, 2013; Tundo and Necci, 2016; PTSD; Brand et al., 2017; Sin and Spain, 2016; Sin et al., 2017; Swan et al., 2017; social anxiety; Michail et al., 2017), no meta-analysis has explored the effectiveness of CBT across the range of anxiety presentations in people with psychosis. A number of systematic reviews have investigated CBT for anxiety in people with psychosis (Braga et al., 2013; Opoka and Lincoln, 2017; Opoka et al., 2018). However, these include limited search strategies and omit relevant studies. The current study aims to extend and update these reviews and use a meta-analysis to explore the pooled effect size. Given the potential role of anxiety in psychosis, we are also interested in examining the impact of CBT for anxiety on psychotic symptoms.

Methods

Protocol and registration

The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO). Registration number CRD42017056250, http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017056250.
Search strategy

Studies were identified via CINAHL Complete, MEDLINE (EBSCO), PsycINFO (EBSCO) and Web of Science. The Cochrane Database of Systematic Reviews, the UK Clinical Research (UKCRN) Study Portfolio and the ISRCTN Registry were also searched. Reference lists were scanned for studies not found electronically.

Literature was searched from the date of inception until 12th November 2018. Automatic alerts were used to identify studies following the database search. The following search terms were used: cognitive behavio* (therap* OR treatment* OR intervention*) OR cognitive (therap* OR treatment* OR intervention*) OR behavio* (therap* OR treatment* OR intervention*) OR CBT AND psychosis OR psychotic OR schizo* OR hallucination* OR delusion* OR paranoi* AND anxi* OR OCD OR "obsessive-compulsive" OR obsession* OR compulsion* OR panic OR agoraphobi* OR "acute stress" OR PTSD OR "post-trauma" OR "posttrauma" OR GAD OR "general anxi*" OR worr* OR phobi* OR "social* anxi*" OR "social* phobi*".

Inclusion and exclusion criteria

Studies were included in the review if they met the following criteria: (1) full text articles in English; (2) randomised controlled trials (RCTs), open trials and case reports; (3) investigating a type or component of CBT; (4) participants (all ages) with a diagnosis of psychosis (including an episode of psychosis, schizophrenia spectrum disorder or mood disorder with psychotic features) or clinically significant levels of psychotic symptoms; (5) participants with a diagnosis of anxiety (as per search terms noted above) or clinically significant levels of anxiety symptoms. For studies with
‘severe mental illness’ samples, only data for participants with psychosis were included, when provided by the corresponding author(s).

Exclusion criteria were as follows: (1) studies primarily focused on ‘at risk’ or ‘ultra high risk’ populations; (2) investigation of stand-alone ‘third-wave’ interventions (e.g. compassion focused therapy, mindfulness); (3) anxiety was not the primary outcome measure; (4) no standardized measure of anxiety was used. Case reports were included in the review to provide an overview of the existing evidence base. However, they were not included in the quantitative synthesis.

**Risk of bias**

The Cochrane risk of bias tool (Higgins et al., 2011) was used to assess risk of bias within controlled and uncontrolled studies. A rating of ‘low’, ‘high’, or ‘unclear’ risk was provided for random sequence generation; allocation concealment; blinding of outcome assessors, incomplete outcome data; selective outcome reporting.

**Data analysis**

Comprehensive Meta-analysis 3.0 was used to analyse data from controlled and uncontrolled trials. Effect sizes (Hedges’ g), the 95% CI and p value were computed using means and standard deviations (SD), standard error or Cohen’s d. A random effects model was used to account for potential heterogeneity.

The primary outcome was anxiety severity and the secondary outcome was psychotic symptom severity. For controlled trials, between-group post-treatment means and SD were used. For uncontrolled trials, pre-post means and SD were used. To enable inclusion of controlled and uncontrolled trials in the same analysis, pre-post
means and SD were also used for the treatment group for controlled trials. Pre-
treatment to follow-up and between-groups follow-up data (including follow-ups 
conducted up to six months post-treatment) were used to investigate treatment 
efficacy over time. Additional analyses were conducted for each type of anxiety using 
the pre-post data for all studies and between-group data for the controlled trials.

Where repeated measures correlations were not available, a conservative 
estimate of 0.7 was used, as suggested by Rosenthal et al. (1993). Heterogeneity was 
assessed using $\Gamma$. As suggested by Higgins et al. (2003), an $\Gamma$ statistic of 25% or less 
was considered low, 50% was considered moderate and 75% was considered high. Publication bias was assessed by visual inspection of funnel plots and Fail-safe N.

Where data were available, reliable and clinical change were calculated for 
anxiety and psychosis data in the case reports at post-treatment and (up to six months) 
follow-up using standardised formula (Jacobson et al., 1984; Jacobson and Truax, 
1991). As suggested by Wise (2004), outcomes were summarised as follows: reliable 
and clinical change (Recovered); reliable or clinical change (Improved); no reliable or 
clinical change (Unchanged); reliable change in a negative direction (Deteriorated).

**Results**

**Search results and study selection**

The study selection process is outlined in Figure 1. The initial search identified 4617 
papers, of which 1408 were duplicates. Twenty-nine studies were included in the 
review and 17 controlled and uncontrolled trials were included in the quantitative
synthesis. Secondary outcome data for van den Berg et al. (2015) was also included in the quantitative synthesis, extracted from de Bont et al. (2016).

Some raw data for participants with psychosis from ‘severe mental illness’ samples were not suitable for inclusion due to insufficient participant numbers (Lu et al., 2012) or no information about diagnosis (Lu et al., 2009; Mueser et al., 2007; Rosenberg et al., 2004). Another study was excluded from the quantitative synthesis due to insufficient data to calculate effect size (Trappler and Newville, 2007).

**Study characteristics**

Study characteristics are outlined in Tables 1 and 2. Of the 29 studies included in the review, nine are controlled trials, eight are uncontrolled trials and 12 are case reports. The 17 studies in the quantitative synthesis involved 664 participants. The most studied type of anxiety was PTSD (n = 7), followed by social anxiety (n = 4), worry (n = 3), OCD (n = 1), panic disorder (n = 1) and anxiety (n = 1). For the controlled studies comparisons were typically made between CBT and treatment as usual (TAU) or wait-list (n = 8). One study (Mueser et al., 2015) compared CBT to a brief intervention including relaxation and psychoeducation. The 12 case reports included 15 participants. Most reports investigated CBT for PTSD (n = 5), followed by OCD, (n = 3), social anxiety (n = 2), panic disorder (n = 1) and specific phobia (n = 1).

Most studies used individual CBT (n = 22) but some used group CBT (n = 6). One study (Freuh et al., 2009) used both individual and group CBT (four vs. eight sessions). Treatment length varied from three (Hagen et al., 2014) to 66 sessions (Keen et al., 2017). Most studies (n = 22) used both cognitive and behavioural components. Two studies (Grubaugh et al., 2016; van den Berg et al., 2015) used
Prolonged Exposure (PE), two studies (Marcello et al., 2009; Mueser et al., 2015) used Cognitive Restructuring (CR), one study used written elaboration and CR (Kevan et al., 2007), one study used systematic desensitisation (Dudley et al., 2005) and one study used Exposure and Response Prevention (ERP; Ekers et al., 2004). Within a programme of CBT, two studies used Imagery Rescripting (ImRs; Callcott et al., 2004; Kayrouz et al., 2015) and one study used Virtual Reality (Gega et al., 2013).

**Risk of bias assessment**

Risk of bias assessment for the controlled and uncontrolled studies is displayed in Table 1. For the controlled studies, risk of bias was mostly low or unclear. Risk of bias varied across the uncontrolled studies, but was mostly high.

**Synthesis of results**

Effect size (Hedges’ g), the 95% CI, p values and I² for each of the outcomes are shown in Table 3. Forest plots are displayed in Figure 2.

**Primary outcomes**

A medium effect was found for the pre-post controlled and uncontrolled anxiety data. However, when only between-group controlled study data were included, a small effect was found. Heterogeneity was moderate to high for the pre-post data, but reduced to low to moderate when only between-group data were included.

Effect size for pre-post controlled and uncontrolled data ranged from medium for panic disorder to large for clinical anxiety. For between-group controlled data, effect size ranged from small for PTSD to medium for social anxiety. At follow-up, a
medium effect was found for pre-post data and a small effect was found for between-group data. Again, heterogeneity was moderate to high for pre-post data, but reduced to low to moderate when only between-group data were included.

Secondary outcomes
A medium effect was found for the pre-post controlled and uncontrolled psychosis data. When only the between-group controlled study data were included, a small effect was found. Heterogeneity was moderate to high for the pre-post data and low when only the between-groups data were included.

Publication bias
Visual inspection of funnel plots did not reveal significant asymmetry for anxiety. For anxiety at post-treatment for the pre-post data, Fail-safe N revealed that 1110 ‘null’ studies would be needed to bring the overall treatment effect to non-significance. However, for the between-group data, Fail-safe N revealed that only 19 ‘null’ studies would be needed to bring the overall treatment effect to non-significance.

Discussion
This review identifies 29 studies that investigate CBT for anxiety in psychosis, with a total of 679 participants. Controlled (n = 9) and uncontrolled (n = 8) studies and case reports (n = 12) were included to provide an overview of the evidence base. Overall, this work highlights the paucity of scientifically rigorous studies in this area. Of the 29 studies included in the review, the following types of anxiety were represented: PTSD (n = 12); social anxiety (n = 6); worry (n = 3); OCD (n = 4), panic disorder (n = 2); clinical anxiety (n = 1) and specific phobia (n = 1).
The quantitative synthesis resulted in a pre-post effect size of 0.74 and a between-groups effect size of 0.35. The between-groups effect size is smaller than those reported in meta-analyses of CBT for anxiety in people without psychosis (i.e. Carpenter et al., 2018; Hedges’ g = 0.56; Hofmann and Smits, 2008; Hedges’ g = 0.73). Although this suggests that CBT for anxiety is less effective in psychosis compared to those without psychosis, only a small number of between-groups studies were available. Although a larger effect size was found for pre-post data, high heterogeneity was found. This is expected given variation in methodology across studies, but suggests these data should be interpreted with caution.

For psychotic symptoms, a medium effect size of 0.57 for pre-post data and a small effect size of 0.37 for between-group data was found. Although the latter finding suggests that CBT for anxiety only has a small effect on psychotic symptoms, a limited number of studies were used in the analysis (n = 6). As with the anxiety data heterogeneity was moderate to high for the pre-post data. Again, this is expected given varied methodology, but it should be considered in interpretation.

Only 13 out of the 29 studies included in the review used measures of psychosis. Although the aim of the studies was not to target psychotic symptoms, including measures of psychosis is important. Omitting such measures means that the overall impact of CBT for anxiety in people with psychosis will not be clear.

**Limitations**

Despite a comprehensive review, only a small number of controlled studies were found. Most studies were uncontrolled trials or case reports, limiting the conclusions that can be drawn. A high risk of bias was found in the uncontrolled studies and high
heterogeneity was found in the combined pre-post data and data for the different types of anxiety. Furthermore, only a small number of data were available for psychotic symptoms and follow-up.

**Future research**

Despite the prevalence and impact of anxiety in people with psychosis, the number of scientifically rigorous studies in this area is low. It is hoped that this work will encourage further research, including well-designed RCTs. The majority of studies identified investigated CBT for PTSD or social anxiety. It is hoped that interested researchers will investigate CBT for other types of anxiety in people with psychosis.

Interestingly, the between-groups effect size found in this meta-analysis is similar to the effect sizes found in meta-analyses investigating CBT for psychosis (e.g. Jauhar et al., 2014, 0.33; van der Gaag et al., 2014, 0.36 for delusions, 0.44 for hallucinations; Wykes et al., 2008, 0.40). It is possible that in people with psychosis CBT is as effective for anxiety as it is for psychotic symptoms. However, due to the lack of scientifically rigorous studies investigating CBT for anxiety in psychosis, this is not clear. Further research is required to gain a better understanding of the efficacy of CBT for anxiety in people with psychosis.

**Conclusion**

This is the first meta-analysis investigating CBT for anxiety in people with psychosis. The review provides an overview of the current evidence base, but in doing so highlights the paucity of scientifically rigorous studies in this area. Further research, including well-designed RCTs, is clearly warranted.
Acknowledgments
The authors would like to thank Catherine Bell and Sarah Howell from the Frank Curtis Library at Norfolk and Suffolk NHS Foundation Trust, for their assistance in sourcing journal articles for the systematic review.

Disclosure of interest
The authors report no conflict of interest.

Funding
There was no funding for this piece of work.

Complying with ethics of experimentation
No studies with human participants or animals were performed by the authors.

Consent
It was not possible or necessary to gain informed consent from any participants.

Health and safety
No experimental work was conducted by the authors.
References


de Bont, P. A. J. M., van den Berg, D. P. G., van der Vleugel, B. M., de Roos, C., de


Romeo GT is not in the garage any more": cognitive behaviour therapy of panic disorder with agoraphobia co morbid with psychosis. *Psychiatra Danubina*, 18(3-4), 205-211. Retrieved from http://www.hdbp.org/psychiatria_danubina/


Lu, W., Fite, R., Kim, E., Hyer, L., Yanos, P. T., Mueser, K. T., & Rosenberg, S. D.


Williams, M. T., Capozzoli, M. C., Buckner, E. V., & Yusko, D. (2015). Cognitive-
treatment of social anxiety disorder and comorbid paranoid schizophrenia.

*Clinical Case Studies, 14*(5), 323-341. doi:10.1177/1534650114559717


Table 1. Study characteristics (controlled and uncontrolled trials).

<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>N</th>
<th>Diagnoses</th>
<th>Mean age (SD)ö</th>
<th>% Maleö</th>
<th>Treatment</th>
<th>Max no. of sessions (mean)</th>
<th>Control group</th>
<th>% attritionö</th>
<th>Outcome measures used</th>
<th>Follow-up (months)ö</th>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Controlled trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foster et al. (2010)</td>
<td>RCT</td>
<td>24</td>
<td>Schizophrenia/schizoaffective disorder/delusional disorder and worry</td>
<td>40.0 (10.0)</td>
<td>58</td>
<td>CBT</td>
<td>4 (*)</td>
<td>TAU</td>
<td>16.7</td>
<td>PSWQ</td>
<td>2</td>
<td>L L H H L</td>
</tr>
<tr>
<td>Freeman et al. (2015)</td>
<td>RCT</td>
<td>150</td>
<td>Schizophrenia/schizoaffective disorder/ delusional disorder and worry</td>
<td>40.9 (10.5)</td>
<td>58</td>
<td>CBT</td>
<td>6 (5.5)</td>
<td>TAU</td>
<td>6</td>
<td>PSWQ</td>
<td>4</td>
<td>L L U L L</td>
</tr>
<tr>
<td>Halperin et al. (2000)</td>
<td>RCT</td>
<td>16</td>
<td>Schizophrenia and social anxiety</td>
<td>39.6 (*)</td>
<td>81.3</td>
<td>CBGT</td>
<td>8 (*)</td>
<td>Waitlist</td>
<td>0</td>
<td>PSWQ</td>
<td>1.5</td>
<td>U U U H L</td>
</tr>
<tr>
<td>Kingsep et al. (2003)</td>
<td>RCT</td>
<td>33</td>
<td>Schizophrenia and social anxiety</td>
<td>(*)</td>
<td>69.7</td>
<td>CBGT</td>
<td>13 (*)</td>
<td>Waitlist</td>
<td>24.2</td>
<td>SIAS</td>
<td>2</td>
<td>U U L L H</td>
</tr>
<tr>
<td>Isham et al. (2018)</td>
<td>RCT</td>
<td>13</td>
<td>Schizophrenia-spectrum disorder and worry</td>
<td>48.0 (*)</td>
<td>*</td>
<td>CBGT</td>
<td>8 (5.7)</td>
<td>Waitlist</td>
<td>7.69</td>
<td>PSWQ</td>
<td>1</td>
<td>U U H L L</td>
</tr>
<tr>
<td>Mueser et al. (2008)</td>
<td>RCT</td>
<td>17</td>
<td>Schizophrenia/schizoaffective disorder and PTSD</td>
<td>44.2 (10.6)</td>
<td>21.3</td>
<td>CBT</td>
<td>12-16 (*)</td>
<td>TAU</td>
<td>49.1</td>
<td>CAPS</td>
<td>6</td>
<td>L L L L L</td>
</tr>
<tr>
<td>Mueser et al. (2015)</td>
<td>RCT</td>
<td>67</td>
<td>Schizophrenia/schizoaffective disorder and PTSD</td>
<td>43.0 (10.5)</td>
<td>33</td>
<td>CR</td>
<td>12-16 (*)</td>
<td>Brief intervention</td>
<td>22.4</td>
<td>CAPS</td>
<td>6, 12</td>
<td>L L L L L</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>n</td>
<td>Diagnosis</td>
<td>Baseline</td>
<td>Intervention</td>
<td>Control</td>
<td>Outcome</td>
<td>Follow-up</td>
<td>Results</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>--------</td>
<td>----</td>
<td>----------------------------------------------------------------------------</td>
<td>----------</td>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steel et al. (2016)</td>
<td>RCT</td>
<td>61</td>
<td>Schizophrenia/schizoaffective disorder and PTSD</td>
<td>42.3 (10.2)</td>
<td>CBT</td>
<td>TAU 23</td>
<td>CAPS-S PANSS (Positive)</td>
<td>6</td>
<td>L L L H L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>van den berg et al. (2015)</td>
<td>RCT</td>
<td>155</td>
<td>Schizophrenia spectrum/psychotic disorders and PTSD</td>
<td>41.2 (10.5)</td>
<td>PE</td>
<td>Waitlist 17.4</td>
<td>CAPS PSYRATS - delusions</td>
<td>6</td>
<td>L L L L L</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Uncontrolled trials**

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>n</th>
<th>Diagnosis</th>
<th>Baseline</th>
<th>Intervention</th>
<th>Control</th>
<th>Outcome</th>
<th>Follow-up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arlow et al. (1997)</td>
<td>OT</td>
<td>8</td>
<td>Schizophrenia and panic disorder</td>
<td>38 (*)</td>
<td>CBGT</td>
<td>N/A 27.28</td>
<td>WASPA 0</td>
<td>H H H H L</td>
<td></td>
</tr>
<tr>
<td>Freuh et al. (2009)</td>
<td>OT</td>
<td>20</td>
<td>Schizophrenia/schizoaffective disorder and PTSD</td>
<td>42.3 (8.4)</td>
<td>CBT (4 sessions) and CBGT (8 sessions)</td>
<td>N/A 35</td>
<td>CAPS 3</td>
<td>H H H U</td>
<td></td>
</tr>
<tr>
<td>Gega et al. (2013)</td>
<td>OT</td>
<td>6</td>
<td>Psychosis and social phobia</td>
<td>* (*) 100</td>
<td>CBT with VR</td>
<td>N/A 0</td>
<td>SIAS 3</td>
<td>H H H L L</td>
<td></td>
</tr>
<tr>
<td>Grubaugh et al. (2016)</td>
<td>OT</td>
<td>34</td>
<td>Psychotic disorder/bipolar disorder or mood disorder with psychotic features and PTSD</td>
<td>47.8 (13.4)</td>
<td>PE 10-15 (7.2)</td>
<td>N/A *</td>
<td>CAPS 6</td>
<td>H H U H L</td>
<td></td>
</tr>
<tr>
<td>Keen et al. (2017)</td>
<td>OT</td>
<td>9</td>
<td>Psychosis and PTSD</td>
<td>37 (11.3)</td>
<td>CBT</td>
<td>N/A 22</td>
<td>PDS 6</td>
<td>H H H L L</td>
<td></td>
</tr>
<tr>
<td>Montreuil et al.</td>
<td>OT</td>
<td>29</td>
<td>Psychosis (n = 23)/ARMS (n = 6) and social anxiety</td>
<td>* (*)</td>
<td>CBGT</td>
<td>N/A 10</td>
<td>SIAS 6</td>
<td>H H U H L</td>
<td></td>
</tr>
</tbody>
</table>

26
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Treatment</th>
<th>Diagnosis/Condition</th>
<th>Sample Size</th>
<th>Age Mean (SD)</th>
<th>Gender</th>
<th>Therapy</th>
<th>Length (duration)</th>
<th>Outcome Measures</th>
<th>Effect Size</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tundo et al. (2014)</td>
<td>OT</td>
<td>21</td>
<td>Schizophrenia/schizoaffective</td>
<td>29 (5.4)</td>
<td>61.9</td>
<td>CBT</td>
<td>8-41 (34.3) schizophrenia; 31.1 schizoaffective</td>
<td>N/A</td>
<td>24</td>
<td>Y-BOCS 12</td>
<td>H H U L L</td>
</tr>
<tr>
<td>Welfare-Wilson and Newman (2013)</td>
<td>OT</td>
<td>7</td>
<td>Psychosis and anxiety</td>
<td>25 (*)</td>
<td>57</td>
<td>CBGT</td>
<td>12 (12)</td>
<td>N/A</td>
<td>DASS-21</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: * = data not available, ARMS = At-Risk Mental State; BSPS = Brief Social Phobia Scale, CAPS = Clinician Administered PTSD Scale, CAPS-S = Clinician Administered PTSD Scale for Schizophrenia, CBT = Cognitive behavioural therapy, CBGT = Cognitive behavioural group therapy, CR = Cognitive Restructuring, DASS-21 = Depression, Anxiety, Stress Scale – Short Form, GPTS = Green et al. Paranoid Thoughts Scale, H = High, L = Low, N/A = not applicable, OCD = obsessive compulsive disorder, OT = open trial, PANSS = Positive and Negative Syndrome Scale, PDS = Post-traumatic Diagnostic Scale, PE = Prolonged Exposure; PSYRATS = Psychotic Symptom Rating Scales, PSWQ = Penn State Worry Questionnaire, PTSD = post-traumatic stress disorder, RCT = randomised controlled trial, SAPS = Scale for the Assessment of Positive Symptoms, SIAS = Social Interaction Anxiety Scale, TAU = Treatment as usual, U = Unclear, VR = Virtual Reality, WASPA = Westergaard Assessment Scale for Panic Attacks, Y-BOCS = Yale-Brown Obsessive Compulsive Scale.

a, b Whereby mean age and gender data presented for intervention and control group only, intervention data are used.

c% attrition based on longest follow-up data available.

dLongest follow-up point recorded.
Only participants with psychosis were included in the quantitative synthesis. The data presented in the table are for the full sample, as raw data on these characteristics were not made available.
Table 2. Study characteristics (Case reports).

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Diagnoses</th>
<th>Age</th>
<th>Gender</th>
<th>Treatment</th>
<th>No. of sessions</th>
<th>Outcome measures used</th>
<th>Follow-up (months)</th>
<th>Clinical change</th>
<th>Reliable change</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Callcott et al. (2004)</td>
<td>1</td>
<td>Psychosis and PTSD</td>
<td>34</td>
<td>F</td>
<td>CBT with ImRs</td>
<td>17</td>
<td>IES</td>
<td>0</td>
<td>*</td>
<td>*</td>
<td>N/A</td>
</tr>
<tr>
<td>Dudley et al. (2005)</td>
<td>1</td>
<td>Paranoid schizophrenia and specific phobia</td>
<td>38</td>
<td>M</td>
<td>Systematic desensitisation</td>
<td>38</td>
<td>MIA</td>
<td>6</td>
<td>*</td>
<td>*</td>
<td>N/A</td>
</tr>
<tr>
<td>Ekers et al. (2004)</td>
<td>1</td>
<td>Schizophrenia and OCD</td>
<td>31</td>
<td>M</td>
<td>ERP</td>
<td>20</td>
<td>Y-BOCS</td>
<td>6</td>
<td>Yc</td>
<td>Yc</td>
<td>Recovered</td>
</tr>
<tr>
<td>Good (2002)</td>
<td>1</td>
<td>Schizophrenia and social phobia</td>
<td>*</td>
<td>M</td>
<td>CBT</td>
<td>16</td>
<td>MFQ</td>
<td></td>
<td></td>
<td></td>
<td>Recovered</td>
</tr>
<tr>
<td>Gruber et al. (2006)</td>
<td>1</td>
<td>Psychosis and panic disorder with agoraphobia</td>
<td>*</td>
<td>M</td>
<td>CBT</td>
<td>19</td>
<td>BAI</td>
<td>3</td>
<td>Yd</td>
<td>Yd</td>
<td>Recovered</td>
</tr>
<tr>
<td>Hagen et al. (2014)</td>
<td>1</td>
<td>Paranoid schizophrenia and OCD</td>
<td>Late</td>
<td>M</td>
<td>CBT with ERP</td>
<td>3</td>
<td>Y-BOCS</td>
<td>6</td>
<td>Ye</td>
<td>Ye</td>
<td>Recovered</td>
</tr>
<tr>
<td>Hamblen et al. (2004)a</td>
<td>2</td>
<td>Bipolar with psychotic features/schizoaffective</td>
<td>43, 56</td>
<td>F, M</td>
<td>CBT</td>
<td>16, 16</td>
<td>CAPS</td>
<td>3, 3</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Study</td>
<td>Diagnosis</td>
<td>N</td>
<td>Gender</td>
<td>Treatment</td>
<td>Outcomes 1</td>
<td>Improvement</td>
<td>Improvement 2</td>
<td>Change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------</td>
<td>---</td>
<td>--------</td>
<td>-------------------------</td>
<td>------------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kayrouz et al. (2015)</td>
<td>Paranoid schizophrenia and PTSD</td>
<td>53</td>
<td>M</td>
<td>CBT with ImRs</td>
<td>IES-R</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kevan et al. (2007)</td>
<td>Schizophrenia and PTSD</td>
<td>31</td>
<td>F</td>
<td>Written trauma elaboration and CR</td>
<td>PDS</td>
<td>Yf</td>
<td>Yf</td>
<td>Recovered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kobori et al. (2008)</td>
<td>Schizophrenia and OCD</td>
<td>26</td>
<td>M</td>
<td>CBT</td>
<td>Y-BOCS</td>
<td>Y</td>
<td>Y</td>
<td>Recovered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marcello et al. (2009)</td>
<td>Schizoaffective disorder and PTSD</td>
<td>In 50’s</td>
<td>M</td>
<td>CR</td>
<td>PCL-S</td>
<td>Y</td>
<td>Y</td>
<td>Recovered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Williams et al. (2015)</td>
<td>Paranoid schizophrenia and social anxiety</td>
<td>22</td>
<td>M</td>
<td>CBT</td>
<td>LSAS</td>
<td>Y</td>
<td>Y</td>
<td>Recovered</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IHS</td>
<td>N</td>
<td>Y</td>
<td>Improved</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: * = data not available to calculate reliable and/or clinical change, BAI = Beck Anxiety Inventory, CAPS = Clinician Administered PTSD Scale, CBT = Cognitive Behavioural Therapy, CR = Cognitive Restructuring, ERP = Exposure and Response Prevention, F = female, IES = Impact of Events Scale, IES-R = Impact of Events Scale – Revised, IHS = Inventory of Hostility and Suspiciousness, ImRs = Imagery Rescripting, KGV = Krawiecka Goldberg Vaughan Scale, LSAS = Liebowitz Social Anxiety Scale, M = male, Mobility Inventory for Agoraphobia, MFQ = Modified Fear Questionnaire, N = No, N/A = Not applicable, OCD = obsessive compulsive disorder, PDS = Post-traumatic Diagnostic Scale, PCL-S = PTSD Checklist - Stressor specific version, PSYRATS = Psychotic Symptom Rating Scales, PTCI – Post-traumatic Cognitions Inventory, PTSD = post-traumatic stress disorder, SANS = Scale for the Assessment of Negative Symptoms, Y = Yes, Yale-Brown Obsessive Compulsive Scale.

a Only two cases used as the first participant did not have a diagnosis of psychosis.

b Clinical change significant only at six month follow-up and not post-treatment.

c Reliable and clinical change found at post-treatment and eight week follow-up.
4 Reliable and clinical change found at post-treatment and three month follow-up.

5 Reliable and clinical change calculated from six-month follow-up data (post-treatment data not presented).

6 Total symptom severity on the PDS used to calculate reliable and clinical change.
Table 3. Results from the quantitative synthesis.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Time Point</th>
<th>Division criteria</th>
<th>Outcome</th>
<th>N</th>
<th>Study codes</th>
<th>Hedges’ g</th>
<th>95% CI</th>
<th>p</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within-group</td>
<td>End of treatment</td>
<td>All studies</td>
<td>Primary measure of anxiety</td>
<td>17</td>
<td>All studies</td>
<td>0.74</td>
<td>0.56, 0.92</td>
<td>&lt;.001</td>
<td>73.25</td>
</tr>
<tr>
<td>(pre-post analysis)</td>
<td></td>
<td>All studies</td>
<td>Positive psychotic symptoms</td>
<td>9</td>
<td>De Bont, Foster, Freeman, Gega, Isham, Keen, Montreuil, Mueser, Steel</td>
<td>0.57</td>
<td>0.36, 0.78</td>
<td>&lt;.001</td>
<td>65.31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Type of anxiety</td>
<td>PTSD</td>
<td>7</td>
<td>Frueh, Grubaugh, Keen, Mueser, Mueser, van den Berg, Steel</td>
<td>0.70</td>
<td>0.37, 1.03</td>
<td>&lt;.001</td>
<td>82.97</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Social Anxiety/Social Phobia</td>
<td>4</td>
<td>Gega, Halperin, Kingsep, Montreuil, Foster, Freeman, Isham</td>
<td>0.71</td>
<td>0.39, 1.02</td>
<td>&lt;.001</td>
<td>57.98</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Worry/GAD</td>
<td>3</td>
<td>Kingsep, Freeman, Montreuil, Foster, Freeman, Isham</td>
<td>0.70</td>
<td>0.20, 1.20</td>
<td>.006</td>
<td>77.19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Panic</td>
<td>1</td>
<td>Arlow</td>
<td>0.66</td>
<td>0.12, 1.20</td>
<td>.017</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OCD</td>
<td>1</td>
<td>Tundo</td>
<td>1.06</td>
<td>0.65, 1.46</td>
<td>&lt;.001</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anxiety NOS</td>
<td>1</td>
<td>Welfare-Wilson</td>
<td>1.14</td>
<td>0.46, 1.83</td>
<td>.001</td>
<td>0</td>
</tr>
<tr>
<td>Follow-up (1-6 mths)</td>
<td></td>
<td>All studies</td>
<td>Primary measure of anxiety</td>
<td>12</td>
<td>Foster, Freeman, Grubaugh, Gega, Freeman, Isham, Keen, Montreuil, Mueser, Steel</td>
<td>0.78</td>
<td>0.56, 0.99</td>
<td>&lt;.001</td>
<td>73.80</td>
</tr>
<tr>
<td>Between-group</td>
<td>End of treatment</td>
<td>All controlled studies</td>
<td>Primary measure of anxiety</td>
<td>9</td>
<td>All controlled studies</td>
<td>0.35</td>
<td>0.07, 0.64</td>
<td>.015</td>
<td>46.91</td>
</tr>
<tr>
<td>(RCTs)</td>
<td></td>
<td>All controlled studies</td>
<td>Positive psychotic symptoms</td>
<td>6</td>
<td>de Bont, Foster, Freeman, Isham, Mueser, Steel</td>
<td>0.37</td>
<td>0.16, 0.57</td>
<td>&lt;.001</td>
<td>0</td>
</tr>
</tbody>
</table>

32
<table>
<thead>
<tr>
<th>Type of anxiety</th>
<th>Follow-up (1-6 mths)</th>
<th>All controlled studies</th>
<th>Primary measure of anxiety</th>
<th># of studies</th>
<th>Mueser, Mueser, van den Berg, Steel Halperin, Kingsep Foster, Freeman, Isham Foster, Freeman, Isham, Mueser, Steel, van den Berg</th>
<th>Mean</th>
<th>95% CI</th>
<th>p-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTSD</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>Mueser, Mueser, van den Berg</td>
<td>0.09</td>
<td>0.50, 0.67</td>
<td>.771</td>
<td>63.10</td>
</tr>
<tr>
<td>Social Anxiety/Social Phobia</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>Halperin, Kingsep</td>
<td>0.58</td>
<td>0.03, 1.14</td>
<td>.041</td>
<td>0</td>
</tr>
<tr>
<td>Worry/GAD</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td>Foster, Freeman, Isham</td>
<td>0.54</td>
<td>0.25, 0.84</td>
<td>&lt;.001</td>
<td>0</td>
</tr>
<tr>
<td>Follow-up (1-6 mths)</td>
<td>All controlled studies</td>
<td></td>
<td></td>
<td>6</td>
<td>Foster, Freeman, Isham, Mueser, Steel, van den Berg</td>
<td>0.34</td>
<td>0.05, 0.63</td>
<td>.022</td>
<td>40.88</td>
</tr>
</tbody>
</table>